1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,600 | 8,000 | 08.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Elicio Therapeutics GAAP EPS of -$0.66 | 2 | Seeking Alpha | ||
| Do | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 121 | GlobeNewswire (Europe) | Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven... ► Artikel lesen | |
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Studienausblick beflügelt: H.C. Wainwright hebt Kursziel für Elicio Therapeutics an | 1 | Investing.com Deutsch | ||
| 17.06. | Elicio Therapeutics Inc.: Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 04.06. | Elicio secures $10 million to extend cash runway | 1 | Investing.com | ||
| 04.06. | Elicio Therapeutics Inc.: Elicio Therapeutics Secures $10 Million in Financing | 1 | GlobeNewswire (USA) | ||
| 04.06. | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Elicio Therapeutics GAAP EPS of -$0.87 | 2 | Seeking Alpha | ||
| 13.05. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.04. | Elicio Therapeutics grants inducement award to new chief strategy and financial officer | 2 | Seeking Alpha | ||
| 16.04. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires | 293 | GlobeNewswire (Europe) | BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 31.03. | Elicio Therapeutics GAAP EPS of -$4.25 misses by $0.29 | 5 | Seeking Alpha | ||
| 31.03. | Elicio Therapeutics, Inc. Loss At -$51.90 Mln In Full Year | 1 | RTTNews | ||
| 31.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 31.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates | 209 | GlobeNewswire (Europe) | Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA")... ► Artikel lesen | |
| 31.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,600 | +3,56 % | EQS-DD: NanoRepro AG: Lisa Jüngst, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.08.2025 / 14:00... ► Artikel lesen | |
| OCUGEN | 0,860 | +0,42 % | Ocugen sichert sich 20 Millionen US-Dollar über registrierte Direktplatzierung | ||
| VIKING THERAPEUTICS | 32,740 | +0,63 % | Doppelschlag mit Viking Therapeutics und Rheinmetall | An der Börse gibt es Momente, in denen wenige Tage über den Erfolg einer ganzen Strategie entscheiden. Wer solche Chancen erkennt und entschlossen handelt, kann in kurzer Zeit außergewöhnliche Ergebnisse... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,900 | -5,84 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,228 | +1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| VAXART | 0,307 | 0,00 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders | - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,160 | -0,85 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| IBIO | 0,488 | -3,37 % | XFRA DIVERSE ISINS: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,956 | +1,37 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,080 | +1,46 % | A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts | ||
| ALDEYRA | 4,450 | -1,42 % | Jones Trading erhöht Kursziel für Aldeyra nach FDA-Annahme auf 9 US-Dollar | ||
| MANNKIND | 3,076 | +1,59 % | MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement | Strengthens MannKind's capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK,... ► Artikel lesen | |
| TRAWS PHARMA | 1,530 | +3,38 % | Traws Pharma, Inc.: Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 | ||
| COHERUS ONCOLOGY | 0,713 | +0,51 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,100 (-1,28 %) liegt der Kurs bei 7,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.